TapewireFind a company

person · Reporting owner

Posard Matthew L.

Disclosed activity across 4 companies

Tapewire entity
36354
SEC CIK
0001543792

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
DermTech, Inc.DMTK · Entity 89998DirectorJune 01, 2023June 05, 2023
HALOZYME THERAPEUTICS, INC.HALO · Entity 793DirectorOctober 01, 2026October 03, 2026
Nautilus Biotechnology, Inc.NAUT · Entity 6679DirectorJune 18, 2026June 22, 2026
Talis Biomedical CorpTLIS · Entity 87664DirectorJune 09, 2023June 12, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

DermTech, Inc.

Report date June 01, 2023 · Filed June 05, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect158,215 Reported balance After 2023-06-01 transaction · row 1
1 source row

Row 1 · 2023-06-01 · Grant · Acquired 35,714 · Balance 158,215

F1: The securities awarded are in the form of restricted stock units issued pursuant to the issuer's 2020 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. The restricted stock units shall vest in four equal quarterly installments over the one-year period following the grant date, subject to the reporting person's continued service. Pursuant to the issuer's Second Amended and Restated Non-Employee Director Compensation Policy, the reporting person elected to defer the receipt of the shares underlying any vested restricted stock units to January 2, 2025.

Filing footnotes · ownership attribution and instrument terms

F1: The securities awarded are in the form of restricted stock units issued pursuant to the issuer's 2020 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. The restricted stock units shall vest in four equal quarterly installments over the one-year period following the grant date, subject to the reporting person's continued service. Pursuant to the issuer's Second Amended and Restated Non-Employee Director Compensation Policy, the reporting person elected to defer the receipt of the shares underlying any vested restricted stock units to January 2, 2025.

HALOZYME THERAPEUTICS, INC.

Report date October 01, 2026 · Filed October 03, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect53,609 Ending reported balance After 2026-10-01 transaction · row 4
4 source rows · reconciled sequence

Row 1 · 2026-10-01 · Sale · Disposed 730 · Balance 58,109

F1: The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1.

F2: Represents a weighted average sales price per share. The shares were sold at prices ranging from $106.930 to $107.660. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Row 2 · 2026-10-01 · Sale · Disposed 3,300 · Balance 54,809

F1: The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1.

F3: Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.990 to $108.930. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Row 3 · 2026-10-01 · Sale · Disposed 1,100 · Balance 53,709

F1: The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1.

F4: Represents a weighted average sales price per share. The shares were sold at prices ranging from $109.040 to $109.970. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Row 4 · 2026-10-01 · Sale · Disposed 100 · Balance 53,609

F1: The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1.

Filing footnotes · ownership attribution and instrument terms

F1: The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1.

F2: Represents a weighted average sales price per share. The shares were sold at prices ranging from $106.930 to $107.660. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3: Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.990 to $108.930. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F4: Represents a weighted average sales price per share. The shares were sold at prices ranging from $109.040 to $109.970. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Nautilus Biotechnology, Inc.

Report date June 18, 2026 · Filed June 22, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.28 · Expires 2036-06-18Direct45,000 Reported balance After 2026-06-18 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-06-18 · Grant · Acquired 45,000 · Balance 45,000

F1: Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month).

Filing footnotes · ownership attribution and instrument terms

F1: Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month).

Talis Biomedical Corp

Report date June 09, 2023 · Filed June 12, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2033-06-09Direct95,000 Reported balance After 2023-06-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2023-06-09 · Grant · Acquired 95,000 · Balance 95,000

F1: 1/12th of the shares subject to the option shall vest monthly over one year from the vesting commencement date.

Filing footnotes · ownership attribution and instrument terms

F1: 1/12th of the shares subject to the option shall vest monthly over one year from the vesting commencement date.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
October 01, 2026 Filed Oct 3, 2026 00:38 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 100 $110.04 $11,004.00
Disclosure

SEC source: 0001159036-26-000133 · wk-form4_1790973495.xml · nonDerivative · entry 4

Posard Matthew L. · CIK 0001543792 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 53,609

F1 · kind: The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1.

Read SEC document
October 01, 2026 Filed Oct 3, 2026 00:38 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 1,100 $109.57 $120,525.90
Disclosure

SEC source: 0001159036-26-000133 · wk-form4_1790973495.xml · nonDerivative · entry 3

Posard Matthew L. · CIK 0001543792 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 53,709

F1 · kind: The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1.

F4 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $109.040 to $109.970. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
October 01, 2026 Filed Oct 3, 2026 00:38 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 3,300 $108.45 $357,898.20
Disclosure

SEC source: 0001159036-26-000133 · wk-form4_1790973495.xml · nonDerivative · entry 2

Posard Matthew L. · CIK 0001543792 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 54,809

F1 · kind: The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1.

F3 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.990 to $108.930. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
October 01, 2026 Filed Oct 3, 2026 00:38 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 730 $107.17 $78,232.64
Disclosure

SEC source: 0001159036-26-000133 · wk-form4_1790973495.xml · nonDerivative · entry 1

Posard Matthew L. · CIK 0001543792 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 58,109

F1 · kind: The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1.

F2 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $106.930 to $107.660. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
September 16, 2026 Filed Sep 17, 2026 21:19 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 4,000 $108.99 $435,964.00
Disclosure

SEC source: 0001159036-26-000123 · wk-form4_1789679983.xml · nonDerivative · entry 4

Posard Matthew L. · CIK 0001543792 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 58,839

F1 · kind: The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1.

F5 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $108.605 to $109.460. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
September 16, 2026 Filed Sep 17, 2026 21:19 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 8,896 $108.04 $961,123.84
Disclosure

SEC source: 0001159036-26-000123 · wk-form4_1789679983.xml · nonDerivative · entry 3

Posard Matthew L. · CIK 0001543792 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 62,839

F1 · kind: The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1.

F4 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.600 to $108.450. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
September 16, 2026 Filed Sep 17, 2026 21:19 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 3,000 $106.83 $320,484.00
Disclosure

SEC source: 0001159036-26-000123 · wk-form4_1789679983.xml · nonDerivative · entry 2

Posard Matthew L. · CIK 0001543792 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 71,735

F1 · kind: The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1.

F3 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $106.580 to $107.310. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
September 16, 2026 Filed Sep 17, 2026 21:19 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 3,100 $106.13 $329,009.20
Disclosure

SEC source: 0001159036-26-000123 · wk-form4_1789679983.xml · nonDerivative · entry 1

Posard Matthew L. · CIK 0001543792 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 74,735

F1 · kind: The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1.

F2 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $105.550 to $106.540. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
June 18, 2026 Filed Jun 22, 2026 20:14 UTC Nautilus Biotechnology, Inc. NAUT · Entity 6679 GrantStock Option (Right to Buy) · Derivative 45,000 $0.00 Strike: $2.28 $0.00
Disclosure

SEC source: 0001543792-26-000002 · wk-form4_1782159249.xml · derivative · entry 1

Posard Matthew L. · CIK 0001543792 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2036-06-18

F1 · derivative.exercise_date: Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month).

Read SEC document
May 05, 2026 Filed May 7, 2026 23:04 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 GrantOption to Purchase Common Stock · Derivative 6,040 $0.00 Strike: $65.87 $0.00
Disclosure

SEC source: 0001159036-26-000064 · wk-form4_1778195074.xml · derivative · entry 2

Posard Matthew L. · CIK 0001543792 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,040

Underlying: Common Stock · 6,040 shares

Expires 2036-05-05

F2 · derivative.exercise_date: Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders.

Read SEC document
May 05, 2026 Filed May 7, 2026 23:04 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 GrantCommon Stock 3,796 $0.00 $0.00
Disclosure

SEC source: 0001159036-26-000064 · wk-form4_1778195074.xml · nonDerivative · entry 1

Posard Matthew L. · CIK 0001543792 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,835

F1 · shares: Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders. These stock units are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director.

Read SEC document
June 23, 2025 Filed Jun 25, 2025 20:37 UTC Nautilus Biotechnology, Inc. NAUT · Entity 6679 GrantStock Option (Right to Buy) · Derivative 45,000 $0.00 Strike: $0.70 $0.00
Disclosure

SEC source: 0001808805-25-000063 · wk-form4_1750883840.xml · derivative · entry 1

Posard Matthew L. · CIK 0001543792 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2035-06-23

F1 · derivative.exercise_date: Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month).

Read SEC document
May 01, 2025 Filed May 2, 2025 20:11 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 GrantOption to Purchase Common Stock · Derivative 5,750 $0.00 Strike: $60.03 $0.00
Disclosure

SEC source: 0001415889-25-011777 · form4-05022025_080510.xml · derivative · entry 2

Posard Matthew L. · CIK 0001543792 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,750

Underlying: Common Stock · 5,750 shares

Expires 2035-05-01

F2 · derivative.exercise_date: Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 1, 2026 and (ii) the date of the Issuer's next annual meeting of stockholders.

Read SEC document
May 01, 2025 Filed May 2, 2025 20:11 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 GrantCommon Stock 4,165 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-011777 · form4-05022025_080510.xml · nonDerivative · entry 1

Posard Matthew L. · CIK 0001543792 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,039

F1 · shares: Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 1, 2026 and (ii) the date of the Issuer's next annual meeting of stockholders. These stock units are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person following completion of service as a director.

Read SEC document
August 14, 2024 Filed Aug 14, 2024 20:57 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 9,881 $57.70 $570,133.70
Disclosure

SEC source: 0001415889-24-021305 · form4-08142024_080823.xml · nonDerivative · entry 3

Posard Matthew L. · CIK 0001543792 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 69,874

F2 · balance_after: Includes 20,722 stock units that are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are scheduled to be released to the reporting person following completion of service as a director.

Read SEC document
August 13, 2024 Filed Aug 14, 2024 20:57 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 10,000 $56.19 $561,930.00
Disclosure

SEC source: 0001415889-24-021305 · form4-08142024_080823.xml · nonDerivative · entry 2

Posard Matthew L. · CIK 0001543792 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,755

F3 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $56.058 to $56.26. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F2 · balance_after: Includes 20,722 stock units that are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are scheduled to be released to the reporting person following completion of service as a director.

Read SEC document
August 12, 2024 Filed Aug 14, 2024 20:57 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 10,000 $55.72 $557,230.00
Disclosure

SEC source: 0001415889-24-021305 · form4-08142024_080823.xml · nonDerivative · entry 1

Posard Matthew L. · CIK 0001543792 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 89,755

F1 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $55.70 to $55.825. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F2 · balance_after: Includes 20,722 stock units that are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are scheduled to be released to the reporting person following completion of service as a director.

Read SEC document
June 14, 2024 Filed Jun 17, 2024 21:03 UTC Nautilus Biotechnology, Inc. NAUT · Entity 6679 GrantStock Option (Right to Buy) · Derivative 45,000 $0.00 Strike: $2.56 $0.00
Disclosure

SEC source: 0001808805-24-000045 · wk-form4_1718658225.xml · derivative · entry 1

Posard Matthew L. · CIK 0001543792 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2034-06-14

F1 · derivative.exercise_date: Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month).

Read SEC document
June 12, 2024 Filed Jun 13, 2024 20:15 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 10,000 $50.62 $506,190.00
Disclosure

SEC source: 0001415889-24-016672 · form4-06132024_080638.xml · nonDerivative · entry 2

Posard Matthew L. · CIK 0001543792 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 99,755

F3 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $50.50 to $50.935. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F2 · balance_after: Includes 20,722 stock units that are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director.

Read SEC document
June 11, 2024 Filed Jun 13, 2024 20:15 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 10,000 $50.01 $500,110.00
Disclosure

SEC source: 0001415889-24-016672 · form4-06132024_080638.xml · nonDerivative · entry 1

Posard Matthew L. · CIK 0001543792 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 109,755

F1 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $50.00 to $50.21. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F2 · balance_after: Includes 20,722 stock units that are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director.

Read SEC document
April 25, 2024 Filed Apr 29, 2024 22:11 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 GrantOption to Purchase Common Stock · Derivative 8,804 $0.00 Strike: $38.46 $0.00
Disclosure

SEC source: 0001415889-24-011705 · form4-04292024_100445.xml · derivative · entry 2

Posard Matthew L. · CIK 0001543792 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,804

Underlying: Common Stock · 8,804 shares

Expires 2034-04-25

F2 · derivative.exercise_date: Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) April 25, 2025 and (ii) the date of the Issuer's next annual meeting of stockholders.

Read SEC document
April 25, 2024 Filed Apr 29, 2024 22:11 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 GrantCommon Stock 6,501 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-011705 · form4-04292024_100445.xml · nonDerivative · entry 1

Posard Matthew L. · CIK 0001543792 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 119,755

F1 · shares: Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) April 25, 2025 and (ii) the date of the Issuer's next annual meeting of stockholders. These stock units are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director.

Read SEC document
June 15, 2023 Filed Jun 16, 2023 23:52 UTC Nautilus Biotechnology, Inc. NAUT · Entity 6679 GrantStock Option (Right to Buy) · Derivative 45,000 $0.00 Strike: $3.97 $0.00
Disclosure

SEC source: 0001808805-23-000062 · wf-form4_168695955711451.xml · derivative · entry 1

Posard Matthew L. · CIK 0001543792 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2033-06-15

F1 · derivative.exercise_date: Subject to reporting person's continuous status as a "Service Provider" (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month).

Read SEC document
June 09, 2023 Filed Jun 12, 2023 21:28 UTC Talis Biomedical Corp TLIS · Entity 87664 GrantStock option (right to buy) · Derivative 95,000 $0.00 Strike: $0.50 $0.00
Disclosure

SEC source: 0001209191-23-036403 · doc4.xml · derivative · entry 1

Posard Matthew L. · CIK 0001543792 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 95,000

Underlying: Common Stock · 95,000 shares

Expires 2033-06-09

F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest monthly over one year from the vesting commencement date.

Read SEC document
June 01, 2023 Filed Jun 5, 2023 22:20 UTC DermTech, Inc. DMTK · Entity 89998 GrantCommon Stock 35,714 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-034582 · doc4.xml · nonDerivative · entry 1

Posard Matthew L. · CIK 0001543792 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 158,215

F1 · shares: The securities awarded are in the form of restricted stock units issued pursuant to the issuer's 2020 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. The restricted stock units shall vest in four equal quarterly installments over the one-year period following the grant date, subject to the reporting person's continued service. Pursuant to the issuer's Second Amended and Restated Non-Employee Director Compensation Policy, the reporting person elected to defer the receipt of the shares underlying any vested restricted stock units to January 2, 2025.

Read SEC document
May 05, 2023 Filed May 9, 2023 22:27 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 GrantOption to Purchase Common Stock · Derivative 11,371 $0.00 Strike: $31.00 $0.00
Disclosure

SEC source: 0001415889-23-007694 · form4-05092023_100504.xml · derivative · entry 2

Posard Matthew L. · CIK 0001543792 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,371

Underlying: Common Stock · 11,371 shares

Expires 2033-05-05

F2 · derivative.exercise_date: Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2024 and (ii) the date of the Issuer's next annual meeting of stockholders.

Read SEC document
May 05, 2023 Filed May 9, 2023 22:27 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 GrantCommon Stock 8,065 $0.00 $0.00
Disclosure

SEC source: 0001415889-23-007694 · form4-05092023_100504.xml · nonDerivative · entry 1

Posard Matthew L. · CIK 0001543792 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 113,254

F1 · shares: Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 5, 2024 and (ii) the date of the Issuer's next annual meeting of stockholders. These stock units are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director.

Read SEC document
December 06, 2022 Filed Dec 7, 2022 00:07 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 10,000 $56.12 $561,180.00
Disclosure

SEC source: 0001415889-22-012142 · form4-12072022_121235.xml · nonDerivative · entry 3

Posard Matthew L. · CIK 0001543792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 105,189

F3 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $56.10 to $56.19. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
December 05, 2022 Filed Dec 7, 2022 00:07 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 10,000 $55.74 $557,370.00
Disclosure

SEC source: 0001415889-22-012142 · form4-12072022_121235.xml · nonDerivative · entry 2

Posard Matthew L. · CIK 0001543792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 115,189

F2 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $55.70 to $55.83. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
December 02, 2022 Filed Dec 7, 2022 00:07 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 10,000 $58.80 $588,000.00
Disclosure

SEC source: 0001415889-22-012142 · form4-12072022_121235.xml · nonDerivative · entry 1

Posard Matthew L. · CIK 0001543792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,189

F1 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $58.80 to $58.83. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
June 15, 2022 Filed Jun 17, 2022 00:04 UTC Nautilus Biotechnology, Inc. NAUT · Entity 6679 GrantStock Option (Right to Buy) · Derivative 86,467 $0.00 Strike: $2.70 $0.00
Disclosure

SEC source: 0001808805-22-000071 · wf-form4_165542423007735.xml · derivative · entry 1

Posard Matthew L. · CIK 0001543792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 86,467

Underlying: Common Stock · 86,467 shares

Expires 2032-06-15

F1 · derivative.exercise_date: Subject to reporting person's continuous status as a "Service Provider" (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month).

Read SEC document
June 10, 2022 Filed Jun 13, 2022 21:41 UTC Talis Biomedical Corp TLIS · Entity 87664 GrantStock Option (right to buy) · Derivative 95,000 $0.00 Strike: $1.00 $0.00
Disclosure

SEC source: 0001209191-22-036425 · doc4.xml · derivative · entry 1

Posard Matthew L. · CIK 0001543792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,000

Underlying: Common Stock · 95,000 shares

Expires 2032-06-09

F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest monthly over one year from the vesting commencement date.

Read SEC document
May 26, 2022 Filed Jun 1, 2022 00:11 UTC DermTech, Inc. DMTK · Entity 89998 GrantCommon Stock 26,480 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-032989 · doc4.xml · nonDerivative · entry 1

Posard Matthew L. · CIK 0001543792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 122,501

F1 · shares: The securities awarded are in the form of restricted stock units issued pursuant to the issuer's 2020 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. The restricted stock units shall vest in four equal quarterly installments over the one-year period following the grant date, subject to the reporting person's continued service. The shares underlying any vested restricted stock units shall be released to the reporting person on May 26, 2023.

Read SEC document
May 05, 2022 Filed May 7, 2022 00:07 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 GrantRestricted Stock Units 6,206 $0.00 $0.00
Disclosure

SEC source: 0001179110-22-002912 · edgar.xml · nonDerivative · entry 1

Posard Matthew L. · CIK 0001543792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 135,189

F1 · shares: Represents annual restricted stock unit grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2023 and (ii) the date of the Issuer's next annual meeting of stockholders.

Read SEC document
December 01, 2021 Filed Dec 2, 2021 02:41 UTC Nautilus Biotechnology, Inc. NAUT · Entity 6679 PurchaseCommon Stock 10,000 $4.45 $44,493.00
Disclosure

SEC source: 0001808805-21-000026 · wf-form4_163841284890930.xml · nonDerivative · entry 4

Posard Matthew L. · CIK 0001543792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Read SEC document
December 01, 2021 Filed Dec 2, 2021 02:41 UTC Nautilus Biotechnology, Inc. NAUT · Entity 6679 PurchaseCommon Stock 10,000 $4.46 $44,612.00
Disclosure

SEC source: 0001808805-21-000026 · wf-form4_163841284890930.xml · nonDerivative · entry 3

Posard Matthew L. · CIK 0001543792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Read SEC document
December 01, 2021 Filed Dec 2, 2021 02:41 UTC Nautilus Biotechnology, Inc. NAUT · Entity 6679 PurchaseCommon Stock 10,000 $4.50 $45,000.00
Disclosure

SEC source: 0001808805-21-000026 · wf-form4_163841284890930.xml · nonDerivative · entry 2

Posard Matthew L. · CIK 0001543792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Read SEC document
November 30, 2021 Filed Dec 2, 2021 02:41 UTC Nautilus Biotechnology, Inc. NAUT · Entity 6679 PurchaseCommon Stock 20,000 $4.57 $91,400.00
Disclosure

SEC source: 0001808805-21-000026 · wf-form4_163841284890930.xml · nonDerivative · entry 1

Posard Matthew L. · CIK 0001543792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Read SEC document
May 26, 2021 Filed May 29, 2021 00:19 UTC DermTech, Inc. DMTK · Entity 89998 GrantCommon Stock 4,661 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-036712 · doc4.xml · nonDerivative · entry 2

Posard Matthew L. · CIK 0001543792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,021

F2 · shares: The securities awarded are in the form of restricted stock units issued pursuant to the issuer's 2020 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. The restricted stock units shall vest, and the shares underlying the restricted stock units shall be released to the reporting person, on January 1, 2023, subject to the reporting person's continued service.

Read SEC document
May 26, 2021 Filed May 29, 2021 00:19 UTC DermTech, Inc. DMTK · Entity 89998 GrantCommon Stock 4,497 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-036712 · doc4.xml · nonDerivative · entry 1

Posard Matthew L. · CIK 0001543792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,360

F1 · shares: The securities awarded are in the form of restricted stock units issued pursuant to the issuer's 2020 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. The restricted stock units shall vest in four equal quarterly installments over the one-year period following the grant date, subject to the reporting person's continued service. The shares underlying any vested restricted stock units shall be released to the reporting person on May 26, 2022.

Read SEC document
May 05, 2021 Filed May 7, 2021 00:04 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 GrantRestricted Stock Units 5,230 $0.00 $0.00
Disclosure

SEC source: 0001179110-21-004974 · edgar.xml · nonDerivative · entry 1

Posard Matthew L. · CIK 0001543792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 128,983

F1 · shares: Represents annual restricted stock unit grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2022 and (ii) the date of the Issuer's next annual meeting of stockholders.

Read SEC document
February 17, 2021 Filed Feb 19, 2021 23:13 UTC Talis Biomedical Corp TLIS · Entity 87664 PurchaseCommon Stock 62,500 $16.00 $1,000,000.00
Disclosure

SEC source: 0001209191-21-012515 · doc4.xml · nonDerivative · entry 1

Posard Matthew L. · CIK 0001543792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,500

Read SEC document
January 11, 2021 Filed Jan 13, 2021 21:21 UTC DermTech, Inc. DMTK · Entity 89998 PurchaseCommon Stock 33,898 $29.50 $999,991.00
Disclosure

SEC source: 0001209191-21-003423 · doc4.xml · nonDerivative · entry 1

Posard Matthew L. · CIK 0001543792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 86,863

F1 · shares: The securities were purchased by the reporting person in an underwritten public offering completed by the Issuer on January 11, 2021.

Read SEC document
June 17, 2020 Filed Jun 19, 2020 20:19 UTC DermTech, Inc. DMTK · Entity 89998 GrantCommon Stock 8,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-037920 · doc4.xml · nonDerivative · entry 1

Posard Matthew L. · CIK 0001543792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,965

F1 · shares: The securities awarded are in the form of restricted stock units issued pursuant to the issuer's 2020 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. All of the restricted stock units shall vest in a single installment on June 17, 2021, subject to the reporting person's continued service through the earlier to occur of (i) June 17, 2021 or (ii) the date of the issuer's 2021 Annual Meeting of Stockholders.

Read SEC document
April 30, 2020 Filed May 1, 2020 23:15 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 GrantRestricted Stock 8,829 $0.00 $0.00
Disclosure

SEC source: 0001179110-20-005382 · edgar.xml · nonDerivative · entry 1

Posard Matthew L. · CIK 0001543792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 123,753

F1 · shares: Represents annual restricted stock grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) April 30, 2021 or (ii) the date of the Issuer's next annual meeting of stockholders.

Read SEC document
April 29, 2020 Filed May 1, 2020 20:24 UTC DermTech, Inc. DMTK · Entity 89998 Exercise / conversionStock Option (right to buy) · Derivative 9,702 $0.00 Strike: $6.94 $0.00
Disclosure

SEC source: 0001209191-20-026533 · doc4.xml · derivative · entry 2

Posard Matthew L. · CIK 0001543792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,702 shares

Expires 2026-09-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This option is fully vested and exercisable.

Read SEC document
April 29, 2020 Filed May 1, 2020 20:24 UTC DermTech, Inc. DMTK · Entity 89998 Exercise / conversionCommon Stock 9,702 $6.94 $67,331.88
Disclosure

SEC source: 0001209191-20-026533 · doc4.xml · nonDerivative · entry 1

Posard Matthew L. · CIK 0001543792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,965

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 30, 2020 Filed Feb 3, 2020 21:15 UTC DermTech, Inc. DMTK · Entity 89998 GrantCommon Stock 6,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-005995 · doc4.xml · nonDerivative · entry 1

Posard Matthew L. · CIK 0001543792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,263

F1 · shares: The securities awarded are in the form of restricted stock units issued pursuant to the issuer's Amended and Restated 2010 Stock Plan. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. Subject to the reporting person's continued service, all of the restricted stock units shall vest in a single installment on the date of the 2020 annual meeting of the stockholders of the issuer.

Read SEC document
December 31, 2019 Filed Jan 3, 2020 21:10 UTC DermTech, Inc. DMTK · Entity 89998 Exercise / conversionRestricted Stock Units · Derivative 15,994 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-000821 · doc4.xml · derivative · entry 2

Posard Matthew L. · CIK 0001543792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,994 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: The shares of Issuer common stock underlying these restricted stock units have fully vested and were released to the reporting person on December 31, 2019.

F2 · derivative.expiration_date: The shares of Issuer common stock underlying these restricted stock units have fully vested and were released to the reporting person on December 31, 2019.

Read SEC document
December 31, 2019 Filed Jan 3, 2020 21:10 UTC DermTech, Inc. DMTK · Entity 89998 Exercise / conversionCommon Stock 15,994 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-20-000821 · doc4.xml · nonDerivative · entry 1

Posard Matthew L. · CIK 0001543792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,263

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.